This course will describe developing standard procedures for handling cultured cells to set up cell-based assays including cell line authentication as a component of assay reproducibility, techniques for measuring cell health and the pathways leading to cytotoxicity, validation of in vitro assays applied to 3D model systems, developing siRNA screening assays, using CRISPR technology as a validation step, and an overview of various GPCR screening methods.

Terry Riss

Global Strategic Manager, Cell HealthPromega Corporation

Dr. Riss received a PhD in Cell Biology from the University of Illinois in 1978 in the field of mammary gland biology. He did postdoctoral work at the University of Texas Medical School in Houston purifying growth factors involved with breast cancer and developing serum-free media formulations to implement bioassays. Dr. Riss moved to the Biotechnology division of Schering Plough in 1988 to develop interleukin/cytokine bioassays to support investigational new drug filings. Dr. Terry Riss started the Cell Biology program at Promega Corporation in 1990 and has held several R&D and Project Management positions. Dr. Riss managed development of cell viability, cytotoxicity, apoptosis, and protease assay systems and also lead efforts to identify and promote multiplexing of cell-based assays to determine the mechanism of cell death. Dr. Riss now serves as Global Strategic Marketing Manager, Cell Health involved in outreach educational training activities. Dr. Riss has participated in several NIH study sections reviewing HTS grants and is co-editor of the cell culture assays section of the Assay Guidance Manual hosted by NIH.

Send Email for Terry Riss

Lisa Minor

PresidentIn Vitro Strategies, LLC

Lisa Minor is President of In Vitro Strategies, LLC, a consulting firm involved in assay development and strategy, screening, technology evaluation, and product marketability assessment. Prior to this position, she was a long term employee of J&J. She is experienced in drug discovery including target validation, assay development, high throughput and safety profiling. At JNJ, she participated in several technology development and evaluation opportunities resulting in marketed products. She was a member of a design team to develop the Seahorse Metabolic profiling instrument used to evaluate energy utilization in cells, partnered with Cellomics to develop the first automated multiwell GPCR internalization imaging assay for screening. She collaborated with Bayer to develop the first multiwell mRNA detection platform using cell lysate with no mRNA extraction (Quantigene), first to show quantifiable intracellular insulin receptor phosphorylation in a multiwell format, collaborated with MDS Sciex and Corning to validate their cell-based label-free impedance systems for GPCRs. She is a past member of the board for the Society for Biomolecular Sciences (SBS) and is a Scientific Advisor for many meetings. She has taught courses for SBS and is well recognized in the field of HTS especially for cell-based assays and has published the book Handbook of Assay Development for Drug Discovery.